(Q41047105)

26 September 2017

1 reference

title

Drug strategies and treatment-resistant schizophrenia (English)

1 reference

26 September 2017

1 reference

C Pantelis

1

1 reference

26 September 2017

T R Barnes

series ordinal

2

1 reference

26 September 2017

publication date

1 February 1996

1 reference

Australian and New Zealand Journal of Psychiatry

26 September 2017

published in

1 reference

26 September 2017

volume

30

1 reference

26 September 2017

issue

1

1 reference

26 September 2017

page(s)

20-37

1 reference

Antipsychotic drugs: clinical pharmacology and therapeutic use.

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Defining treatment refractoriness in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Response to neuroleptic drugs as a device for classifying schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Defining treatment refractoriness in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Short-term outcome in trial entrants and trial eligible patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Long-acting oral vs injectable antipsychotic drugs in schizophrenics: a one-year double-blind comparison in multiple episode schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Molecular pathology of schizophrenia: more than one disease process?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Mechanism of the antipsychotic effect in the treatment of acute schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Negative and deficit symptoms in schizophrenia do respond to neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Neuroleptic responsivity of negative and positive symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptics and signs of organic dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

The neurodevelopmental basis of sex differences in schizophrenia1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Butaperazine pharmacokinetics. Effect of dosage regimen on steady state blood levels

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Neuroleptics and the Natural Course of Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Practical ways of alleviating auditory hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

The omnipotence of voices. A cognitive approach to auditory hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

When Symptoms Persist: Choosing Among Alternative Somatic Treatments for Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

The use of high-dose antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Treatment of Resistant Schizophrenics With Extreme High Dosage Fluphenazine Hydrochloride

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

High Dosage Haloperidol in Chronic Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

A controlled dose comparison of haloperidol in newly admitted schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Dosage of haloperidol for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

The Mechanism of Action of Novel Antipsychotic Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Schizophrenia as a brain disease. The dopamine receptor story

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

New Antipsychotics: Classification, Efficacy, and Adverse Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Clozapine. A novel antipsychotic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Who should receive clozapine?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Update on the clinical efficacy and side effects of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Agranulocytosis in patients treated with clozapine. A study of the Finnish epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Leponex--associated granulocytopenia: a review of the situation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Clozapine-induced agranulocytosis: a situation report up to August 1976.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Dopamine D4 receptors elevated in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Clozapine: neuroleptic-induced EPS and tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

The effects of clozapine on tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Clozapine and haloperidol in the amygdaloid complex: differential effects on dopamine transmission with long-term treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

A long-term study of remoxipride in chronic schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Zetidoline, a new antipsychotic. First controlled trial in acute schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

One more look at propranolol for the treatment of refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Lithium combined with haloperidol in schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Lithium Carbonate, Haloperidol, and Irreversible Brain Damage

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Carbamazepine in treatment of violent schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Carbamazepine for the violent psychiatric patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Efficacy of adjunctive carbamazepine in the treatment of chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Serum homovanillic acid concentrations in carbamazepine-treated chronic schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Carbamazepine maintenance treatment in outpatient schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Case report of a possible interaction between neuroleptics and carbamazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Lithium-carbamazepine neurotoxicity and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Diazepam in schizophrenia: a preliminary double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Diazepam in high doses is effective in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Anxiety in schizophrenia. The responses to chlordiazepoxide in an intensive design study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Clonazepam/haloperidol combination therapy in schizophrenia: a double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Effect of the benzodiazepine derivative estazolam in patients with auditory hallucinations. A multicentre double-blind, cross-over study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

Treatment of the neuroleptic-nonresponsive schizophrenic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048679609076070

10.3109/00048679609076070

21 January 2018

Identifiers

DOI

1 reference

release_vx4jnh6kmrcg3eapqqac7kaxki

26 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vx4jnh6kmrcg3eapqqac7kaxki

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference